arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Aclarion, Inc.

ACON
$2.95 ▲ +0.33 (+12.38%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
6 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Aclarion, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.6M
Dividend Yield —
Revenue Growth 65.6% ↗
Op. Margin —
ROIC -54.9% ↗
FCF / Share $-13.51
Trailing P/E —
Price / Book 0.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$75.73K
↑ +65.6% —
Net Income Profit after all expenses
$-7.23M
↓ -3.4% —
FCF / Share Free cash flow per share
$-13.51
↓ -4.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 6 years · 23 quarters